LTBP4: A Protein as A Potential Drug Target Or Biomarker (G8425)

Target Name: LTBP4

NCBI ID: G8425

LTBP4

Other Name(s): LTBP4 variant 1 | ARCL1C | Latent transforming growth factor beta binding protein 4, transcript variant 1 | Latent transforming growth factor beta binding protein 4, transcript variant 2 | Latent transforming growth factor-beta binding protein 4L | Latent transforming growth factor beta binding protein 4 | LTBP-4 | LTBP4S | LTBP4_HUMAN | LTBP4L | Latent-transforming growth factor beta-binding protein 4 | latent transforming growth factor-beta binding protein 4L | Latent-transforming growth factor beta-binding protein 4 (isoform b) | LTBP4 variant 2 | Latent-transforming growth factor beta-binding protein 4 (isoform a) | latent transforming growth factor beta binding protein 4

LTBP4: A Protein as A Potential Drug Target Or Biomarker

LTBP4 (LTBP4 variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the Li-Frazer family of proteins, which are characterized by the presence of a long terminal piece (LTBP4) in their sequence.

The LTBP4 protein is known for its role in the regulation of cellular processes that are important for both the survival and the integrity of tissues. It has been shown to play a role in the development and progression of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of the LTBP4 protein is its ability to interact with other proteins that are important for cellular signaling and signaling pathways. This interaction with other proteins has led to the identification of LTBP4 as a potential drug target or biomarker for a number of diseases.

One of the potential benefits of targeting LTBP4 is its potential to treat a variety of diseases that are characterized by the over-expression or dysfunction of genes that are involved in cellular signaling pathways. For example, LTBP4 has been shown to be involved in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By targeting LTBP4, researchers may be able to develop new treatments for these conditions.

In addition to its potential as a drug target, LTBP4 has also been identified as a potential biomarker for a number of diseases. The ability of LTBP4 to interact with other proteins that are involved in cellular signaling pathways makes it a potential marker for a variety of diseases, including neurodegenerative disorders, cancer, and autoimmune disorders.

One of the key challenges in studying LTBP4 is its relatively high level of expression in a variety of tissues, which can make it difficult to study its effects in specific cell types or contexts. However, researchers are continuing to work on developing methods to study LTBP4 and its potential as a drug target or biomarker.

In conclusion, LTBP4 is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its ability to interact with other proteins that are involved in cellular signaling pathways makes it a promising target for researchers who are working to develop new treatments for a range of conditions. Further research is needed to fully understand the effects of LTBP4 and its potential as a drug or biomarker.

Protein Name: Latent Transforming Growth Factor Beta Binding Protein 4

Functions: Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space. Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta

The "LTBP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTBP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets